| Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis KL Cooper, J Madan, S Whyte, MD Stevenson, RL Akehurst BMC cancer 11, 1-11, 2011 | 328 | 2011 |
| British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection … MD Rutter, J East, CJ Rees, N Cripps, J Docherty, S Dolwani, PV Kaye, ... Gut 69 (2), 201-223, 2020 | 235 | 2020 |
| Distributional cost‐effectiveness analysis of health care programmes–a methodological case study of the UK bowel cancer screening programme M Asaria, S Griffin, R Cookson, S Whyte, P Tappenden Health economics 24 (6), 742-754, 2015 | 142 | 2015 |
| Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible … L Sharp, L Tilson, S Whyte, A O'Ceilleachair, C Walsh, C Usher, ... British journal of cancer 106 (5), 805-816, 2012 | 113 | 2012 |
| Bayesian calibration of a natural history model with application to a population model for colorectal cancer S Whyte, C Walsh, J Chilcott Medical decision making 31 (4), 625-641, 2011 | 85 | 2011 |
| Cost of care for colorectal cancer in Ireland: a health care payer perspective L Tilson, L Sharp, C Usher, C Walsh, A O’Ceilleachair, C Stuart, ... The European journal of health economics 13, 511-524, 2012 | 77 | 2012 |
| Cost-effectiveness of granulocyte colony–stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom S Whyte, KL Cooper, MD Stevenson, J Madan, R Akehurst Value in Health 14 (4), 465-474, 2011 | 74 | 2011 |
| Eliciting societal preferences for weighting QALYs for burden of illness and end of life D Rowen, J Brazier, C Mukuria, A Keetharuth, A Risa Hole, A Tsuchiya, ... Medical Decision Making 36 (2), 210-222, 2016 | 62 | 2016 |
| Reappraisal of the options for colorectal cancer screening in England S Whyte, J Chilcott, S Halloran Colorectal Disease 14 (9), e547-e561, 2012 | 57 | 2012 |
| Consistency between direct and indirect trial evidence: is direct evidence always more reliable? J Madan, MD Stevenson, KL Cooper, AE Ades, S Whyte, R Akehurst Value in Health 14 (6), 953-960, 2011 | 52 | 2011 |
| Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal S Whyte, A Pandor, M Stevenson Pharmacoeconomics 30, 1119-1132, 2012 | 46 | 2012 |
| Estimating the cost-effectiveness of implementation: is sufficient evidence available? S Whyte, S Dixon, R Faria, S Walker, S Palmer, M Sculpher, S Radford Value in Health 19 (2), 138-144, 2016 | 37 | 2016 |
| The costs and benefits of risk stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis C Thomas, O Mandrik, CL Saunders, D Thompson, S Whyte, S Griffin, ... Cancer Prevention Research 14 (8), 811-822, 2021 | 34 | 2021 |
| Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation B Kearns, J Chilcott, S Whyte, L Preston, S Sadler BMC medicine 14, 1-10, 2016 | 32 | 2016 |
| Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer S Whyte, A Pandor, M Stevenson, A Rees Health Technology Assessment 14 (2), 47-53, 2010 | 31 | 2010 |
| Virtual chromoendoscopy for the real-time assessment of colorectal polyps in vivo: a systematic review and economic evaluation J Picot, M Rose, K Cooper, K Pickett, J Lord, P Harris, S Whyte, D Bohning, ... Health Technology Assessment 21 (79), 2017 | 30 | 2017 |
| Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland L Sharp, L Tilson, S Whyte, AO Ceilleachair, C Walsh, C Usher, ... BMC health services research 13, 1-12, 2013 | 29 | 2013 |
| Getting cost-effective technologies into practice: the value of implementation. Report on framework for valuing implementation initiatives S Walker, R Faria, S Whyte, S Dixon, S Palmer, M Sculpher The University of Sheffield, 2024 | 25 | 2024 |
| How to invest in getting cost-effective technologies into practice? A framework for value of implementation analysis applied to novel oral anticoagulants R Faria, S Walker, S Whyte, S Dixon, S Palmer, M Sculpher Medical Decision Making 37 (2), 148-161, 2017 | 22 | 2017 |
| Effectiveness and cost-effectiveness of an awareness campaign for colorectal cancer: a mathematical modeling study S Whyte, S Harnan Cancer Causes & Control 25, 647-658, 2014 | 22 | 2014 |
